



国内版

国际版

Is there a role today for mycophenolate in the treatment of ANCA Associated Vasculitis



All

Images

Videos

翻译成中文

关闭取词

19,500 Results

Any time ▼

Management of ANCA-associated vasculitis: Current trends ...

www.ncbi.nlm.nih.gov › ... › Ther Clin Risk Manag › v.6; 2010

Jun 24, 2010 · The antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) are characterized by the production of ANCA, reactive to either proteinase-3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA), which are constituents of neutrophil granules and monocyte lysosomes.

Cited by: 19

Author: Sally M A Hamour, Alan David Salama, C...

Publish Year: 2010

Update on the treatment of ANCA associated vasculitis

https://www.researchgate.net/publication/277340025_Update_on_the...

Background and objectives: **Treatment** with azathioprine within 3 months of remission induction with cyclophosphamide is a common **treatment** strategy for patients with **ANCA-associated vasculitis**.

Maintenance of Remission in ANCA-Associated Vasculitis ...

<https://www.the-rheumatologist.org/article/maintenance-of-...> ▼

Whether there is a **role** for high-dose sulfamethoxazole-trimethoprim (one double-strength tablet twice daily) in addition to an immune-suppressive drug continues to be a source of debate, but this drug at this strength should not be used in combination with methotrexate.

ANCA Vasculitis & ANCA Associated Vasculitis Symptoms ...

<https://healthjade.com/anca-vasculitis> ▼

ANCA vasculitis & ANCA associated vasculitis. Learn about symptoms, causes, diagnosis, **treatment**, and types of **anca associated vasculitis**, **p-anca vasculitis** and **c-anca vasculitis**. ... **There** may be normocytic anemia, thrombo-cytosis, elevated erythrocyte sedimentation rate, increased liver function, or evidence of renal involvement ...

Treatment of renal manifestations of ANCA-associated ...

www.ncbi.nlm.nih.gov › ... › J Nephrol › v.2(1); 2013 Jan

Jan 01, 2013 · 3.2. Renal features. The kidney is the most commonly affected vital organ in **ANCA-associated vasculitis**, and patient outcomes are largely determined by the severity of renal disease at diagnosis and by its response to **treatment**.

Cited by: 4

Author: Kresimir Galesic, Danica Ljubanovic, Ivic...

Publish Year: 2013

Name of Journal: *World Journal of Nephrology*

Manuscript NO: 46990

Manuscript Type: MINIREVIEWS

The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody associated vasculitis

Koukoulaki M *et al.* Mycophenolate in ANCA-AAV

Maria Koukoulaki, Christos Iatrou

Abstract

Mycophenolic acid, the active metabolite for mycophenolate mofetil and mycophenolic sodium, is a strong, non competitive, reversible inhibitor of

Match Overview

1	Internet 18 words crawled on 20-Feb-2019 www.chpw.org	1%
2	Internet 18 words crawled on 21-Dec-2017 www.karger.com	1%
3	Internet 17 words crawled on 02-Nov-2018 archive.org	1%
4	Crossref 14 words Sebastian E. Sattui, Robert F. Spiera. "Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis", Rheu	<1%
5	Crossref 12 words P. C. Baer. "Effects of mycophenolic acid on human renal proximal and distal tubular cells in vitro", Nephrology Dialysis	<1%



国内版

国际版

The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody



All

Images

Videos

翻译成中文

关闭取词

39,000 Results

Any time ▾

Introduction. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a disease process characterized by necrotizing inflammation of small vessels, the relative paucity of immune deposits and an association with detectable circulating ANCAs. Three subtypes have been described; granulomatosis with polyangiitis (GPA,...

[Recent advances in anti-neutrophil cytoplasmic antibody ...](#)

www.ncbi.nlm.nih.gov/pmc/articles/PMC4795442/

Is this answer helpful?  

[Treatment of Antineutrophil Cytoplasmic Antibody ...](#)

[https://www.rheumatic.theclinics.com/article/S0889-857X\(19\)30033-X/fulltext](https://www.rheumatic.theclinics.com/article/S0889-857X(19)30033-X/fulltext)

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic necrotizing vasculitides that includes granulomatosis with polyangiitis, microscopic

[Recent advances in anti-neutrophil cytoplasmic antibody ...](#)

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795442>

Anti-neutrophil cytoplasmic antibody-associated vasculitis is an uncommon inflammatory disease of small to medium-sized vessels that frequently presents with rapidly progressive glomerulonephritis and renal failure though it can affect any organ system. If untreated, the ...

[Treatment of Antineutrophil Cytoplasmic Antibody ...](#)

[https://www.rheumatic.theclinics.com/article/S0889-857X\(19\)30033-X/pdf](https://www.rheumatic.theclinics.com/article/S0889-857X(19)30033-X/pdf) ▾

Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Is There Still a Role for Cyclophosphamide? Sebastian E. Sattui, MDa,* , Robert F. Spiera, ...

[Mycophenolate Mofetil in the Treatment of Ocular ...](#)

<https://www.liebertpub.com/doi/abs/10.1089/jop.2007.0055>

Aim: The aim of this study was to describe the use of mycophenolate mofetil (MMF) in the treatment of patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis with ocular involvement. Methods: A retrospective review was performed. Ocular and systemic manifestations, history of previous immunosuppressive drug therapy, concurrent therapy with MMF, response to



40,500 Results

Any time ▾

Introduction. Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a disease process characterized by necrotizing inflammation of small vessels, the relative paucity of immune deposits and an association with detectable circulating ANCAs. Three subtypes have been described; granulomatosis with polyangiitis (GPA,...

Recent advances in anti-neutrophil cytoplasmic antibody ...

www.ncbi.nlm.nih.gov/pmc/articles/PMC4795442/

Is this answer helpful?

Treatment of Antineutrophil Cytoplasmic Antibody ...

[https://www.rheumatic.theclinics.com/article/S0889-857X\(19\)30033-X/fulltext](https://www.rheumatic.theclinics.com/article/S0889-857X(19)30033-X/fulltext)

Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a group of systemic necrotizing vasculitides that includes granulomatosis with polyangiitis, microscopic

Recent advances in anti-neutrophil cytoplasmic antibody ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4795442/>

Anti-neutrophil cytoplasmic antibody-associated vasculitis is an uncommon inflammatory disease of small to medium-sized vessels that frequently presents with rapidly progressive glomerulonephritis and renal failure though it can affect any organ system. If untreated, the ...

Induction of remission in active anti-neutrophil ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1954648>

Table 3 Efficacy of mycophenolate mofetil as remission induction treatment in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis* Overall, remission was successfully induced in 70% of these 46 patients (range 33–82).

Cited by: 141

Author: Patricia M Stassen, Jan Willem Cohen Te...

Publish Year: 2007

Treatment of Antineutrophil Cytoplasmic Antibody ...

<https://jamanetwork.com/journals/jama/fullarticle/208292> ▾

Aug 08, 2007 · Context Immunosuppressive therapies for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis have greatly advanced patient survival but have turned ANCA-associated vasculitis (AAV) into chronic, relapsing disorders. Long-term treatment and disease-related morbidity are major threats.

Cited by: 236

Author: Xavier Bosch, Antonio Guilabert, Gerard ...

Publish Year: 2007

Author: Xavier Bosch, MD, PhD